Clinical Trials Logo

Filter by:
NCT ID: NCT03923855 Not yet recruiting - Clinical trials for Improvement of Abdomen Appearance

Clinical Evaluation of the BTL-899 Device for Non-invasive Lipolysis on Human Fat Tissue

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

The subjects will be enrolled and assigned to a single study group. They will be required to complete two treatment visits and come for a biopsy procedure.

NCT ID: NCT03922425 Active, not recruiting - Schizophrenia Clinical Trials

Community-based Mental Health Care for People With Severe and Enduring Mental III Health

RECOVER-E
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

A single-blinded hybrid effectiveness-implementation trial (Type II), that both evaluates the intervention outcomes (clinical and service use outcomes) through patient-randomization in the implementation sites, as well as evaluates the implementation strategy chosen for the intervention and its impact on implementation outcomes (e.g. adoption, fidelity, acceptability and maintenance (continued implementation) of the intervention).

NCT ID: NCT03906799 Recruiting - Atrial Fibrillation Clinical Trials

Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)

PROMISE-AF
Start date: March 19, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, dose-finding, placebo-controlled, parallel group, multicenter, phase II study to evaluate the efficacy, safety, and popPK of three different doses of OMT-28 given once daily versus placebo in patients with persistent AF.

NCT ID: NCT03901729 Not yet recruiting - Heart Failure (HF) Clinical Trials

A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

AVANTI
Start date: May 15, 2019
Phase: Phase 2
Study type: Interventional

To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.

NCT ID: NCT03891524 Not yet recruiting - Clinical trials for Arthroplasty, Replacement, Knee

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

Start date: June 13, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment or objectively confirmed symptomatic], nonfatal pulmonary embolism [PE]), or any death during the treatment period.

NCT ID: NCT03877224 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Start date: April 4, 2019
Phase: Phase 3
Study type: Interventional

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF)

NCT ID: NCT03875235 Recruiting - Clinical trials for Biliary Tract Neoplasms

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

TOPAZ-1
Start date: April 16, 2019
Phase: Phase 3
Study type: Interventional

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

NCT ID: NCT03855865 Not yet recruiting - Clinical trials for Depressive Disorder, Major

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

Start date: April 22, 2019
Phase: Phase 3
Study type: Interventional

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to 10 mg of Vortixetine and placebo in participants with major depressive disorder (MDD).

NCT ID: NCT03852160 Not yet recruiting - Clinical trials for Depressive Disorder, Treatment-Resistant

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Start date: May 22, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate to severe depressive episode with flexibly-dosed esketamine nasal spray plus a newly initiated oral standard-of-care AD compared with placebo nasal spray plus a newly-initiated standard-of-care oral AD, in achieving remission and staying relapse-free after remission.

NCT ID: NCT03846219 Recruiting - Clinical trials for Relapsing-Remitting Multiple Sclerosis (RRMS)

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

EMPhASIS
Start date: January 28, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), 30 mg/day and 45 mg/day, in patients with RRMS and evidence of active disease. The trial consists of a screening period, a blinded 24-week main treatment period, and an optional initially blinded, then open-label extended treatment period of up to 9.5 years. About 40 centers are planned to participate in Romania, Bulgaria, Ukraine, and Poland; potential additional centers in Hungary and Croatia. In total, 195 patients are planned to be randomized 1:1:1 to treatment with 30 mg/day or 45 mg/day IMU-838, or placebo (65 patients each) in the main treatment period. During the extended treatment period, patients will be re-randomized such that patients previously on placebo will be re-randomized 1:1 to treatment with 30 g/day or 45 mg/day IMU-838, all other patients will be re-randomized to the same treatment they previously received.